Zydus Lifesciences Ltd received tentative approval from the USFDA on June 2, 2025, for its Rifaximin Tablets (550 mg), which treat irritable bowel syndrome. The US sales for Rifaximin tablets were USD 2,672.9 million as of March 2025.
AI Assistant
Zydus Lifesciences Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.